1
Terauchi Jun, Kuno Haruhiko, Nara Hiroshi, Oki Hideyuki, Sato Kenjiro: Heterocyclic amide compound and use thereof as an mmp-13 inhibitor. Takeda Pharmaceutical Company, Terauchi Jun, Kuno Haruhiko, Nara Hiroshi, Oki Hideyuki, Sato Kenjiro, TAKASHIMA Hajime, November 10, 2005: WO/2005/105760 (67 worldwide citation)

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionall ...


2
Urano Yasuharu, Satoh Shigeki, Ishibashi Naoki, Kamijo Kazunori: (hdac) Inhibitors. Astellas Pharma, Urano Yasuharu, Satoh Shigeki, Ishibashi Naoki, Kamijo Kazunori, TAKASHIMA Hajime, July 29, 2004: WO/2004/063169 (58 worldwide citation)

A compound having the following formula (I): wherein R¿1? is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s), R¿2? is hydroxyamino, R¿3? is hydrogen or a suitable substituent, L¿1? is -(CH?2#191)?n#191- (wherein n is an integer of 0 to 6) option ...


3
Cho Nobuo, Kasai Shizuo, Yamashita Toshiro: (Ja) 糖尿病の予防・治療剤, (En) Prophylactic/therapeutic agent for diabetes. Takeda Pharmaceutical Company, Cho Nobuo, Kasai Shizuo, Yamashita Toshiro, TAKASHIMA Hajime, October 5, 2006: WO/2006/104280 (57 worldwide citation)

(EN) A 11&bgr;-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1) or a salt thereof or a prodrug of the compound or salt. The inhibitor has an excellent activity and is useful as a prophylactic/therapeutic agent for diabetes, insulin resistance, obesity, a ...


4

5
Yoshinari Tomohiro, Uchiyama Yoshihiro: (Ja) シームレスカプセル, (En) Sealmess capsule. Takeda Pharmaceutical Company, Yoshinari Tomohiro, Uchiyama Yoshihiro, TAKASHIMA Hajime, January 8, 2009: WO/2009/004999 (48 worldwide citation)

(EN) Disclosed is a seamless capsule which can be produced without using any interfacial tension regulator or gelation accelerator. Specifically disclosed is a seamless capsule comprising: a shell formed by a shell composition comprising a gelatin and a plasticizer and containing no interfacial tens ...


6
Oi Satoru, Maezaki Hironobu, Suzuki Nobuhiro: Pyridine compounds as inhibitors of dipeptidyl peptidase iv. Takeda Pharmaceutical Company, Oi Satoru, Maezaki Hironobu, Suzuki Nobuhiro, TAKASHIMA Hajime, May 12, 2005: WO/2005/042488 (46 worldwide citation)

A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hyd ...


7
Urano Yasuharu, Hosaka Mitsuru, Inoue Takayuki, Osoda Kazuhiko, Sawada Kozo, Kuroda Akio: (hdac) Inhibitors. Fujisawa Pharmaceutical, Urano Yasuharu, Hosaka Mitsuru, Inoue Takayuki, Osoda Kazuhiko, Sawada Kozo, Kuroda Akio, TAKASHIMA Hajime, August 26, 2004: WO/2004/072047 (46 worldwide citation)

A compound of the following formula (I):whereinR1 is acyl, R2 is hydrogen, orR1 and R2 are linked together to form a heterocyclic ring, R5 is hydroxy, hydroxylamino, lower alkyl, lower alkoxy, halo(lower)alkyl or hydroxy(lower)alkyl, Q is lower alkylene or lower alkenylene, andG is a substituent sel ...


8

9

10
Yasuma Tsuneo, Miyamoto Yasufumi: Fused heterocyclic compound. Takeda Pharmaceutical Company, Yasuma Tsuneo, Miyamoto Yasufumi, TAKASHIMA Hajime, April 24, 2008: WO/2008/047821 (41 worldwide citation)

Disclosed is a glucokinase activator which is useful as a pharmaceutical agent such as a prophylactic/therapeutic agent for diabetes, obesity or the like. Specifically disclosed is a glucokinase activator comprising a compound represented by the formula (I), a salt thereof, or a prodrug of the compo ...